drugset / Trial / NCT04636008
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
Phase 1/2
Recruiting
20 enrolled
West China Hospital
Chengdu Third People's Hospital · collabFirst Affiliated Hospital of Chongqing Medical University · collabSichuan Cancer Hospital and Research Institute · collabThe Affiliated Hospital Of Southwest Medical University · collabYunnan Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This prospective, single-arm study is conducted to investigate the safety and efficacy of Sintilimab combined with hypofractionated radiotherapy in patients with microsatellite instability-high (MSI-H)/ DNA mismatch repair-deficient (dMMR) non-metastatic rectal cancer.
Timeline
- Start
- 2020-08-14
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |